SAN RAFAEL, Calif. , July 30, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a...
ReNU syndrome was discovered in 2024 and there are no medicines approved for the condition
2 Reasons to Avoid BMRN and 1 Stock to Buy Instead
Application based on long-term safety and efficacy data from three ongoing studies, including adult height and additional clinical outcomes beyond linear growth, including body proportionality and arm...
1 of Wall Street’s Favorite Stocks with Competitive Advantages and 2 We Avoid
2 Cash-Heavy Stocks with Exciting Potential and 1 We Ignore
2 Healthcare Stocks for Long-Term Investors and 1 We Brush Off
Therapeutics Stocks Q1 Teardown: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest
Data from an investigator-led study showed treatment with VOXZOGO resulted in sustained improvements in growth over three years in children with hypochondroplasia
2 Profitable Stocks Worth Your Attention and 1 We Find Risky